| 2026 |
- Completion of new headquarters in Magok, “Bio Innovation Hub”
- First patient dosed in Phase 1/2a trial of head and neck cancer therapeutic vaccine 'BVAC-E6E7'
- Expansion of global vaccine platform patent portfolio (patents secured in the U.S., Brazil, Russia, Vietnam, and Singapore)
- Participation in a project led by the Korea Disease Control and Prevention Agency (KDCA), National Institute of Health, for the development of a Marburg virus vaccine candidate
- Selected for the 1st 2026 National Drug Development Program (KDDF) – 'BVAC-HPVmi'
|
| 2025 |
- Initiation of Phase 1 Clinical Trial for BVAC-E6E7 (December 18)
- Selection for the National Drug Development Project by the Korea Drug Development Fund (October 15)
|
| 2024 |
- Interim results of 'BVAC-C' combination therapy orally presented at ASCO
- Acquisition and merger with Forbaker Co., Ltd.
-
|
| 2023 |
- Approval of phase 3b clinical trial for 'AdCLD-CoV19-1', COVID-19 prevention vaccine
- Selected for Korea Health Industry Development Institute (KHIDI) National R&D Project (Apr 1)
|
| 2022 |
- Expansion of patent filings related to vaccine platforms and cancer immunotherapeutic vaccines
- Commencent of phase 2b clinical trial for 'AdCLD-CoV19-1 OMI', COVID-19 prevention vaccine
|
| 2021 |
- Commencement of COVID-19 vaccine phase 2a clinical trial
- Selected by Korea Drug Development Fund of the Ministry of Health and Welfare for COVID-19 preventive vaccine clinical support (Phase 1/2)
- Commencement of COVID-19 vaccine phase 1 clinical trial
|
| 2020 |
- Approval of phase 1/2a clinical trial for COVID-19 prevention vaccine (December 4)
- Completion of Vaccine & Cell Genetic Treatment GMP Center
- Selected by the Ministry of Science and ICT for developing original technology of COVID-19 and variants prevention vaccine
- Completion of phase 1 clinical trial for BVAC-B
- Approval of Phase 1 clinical trial for BVAC-P
|
| 2019 |
-
- Signed contract for Seongnam SK V1 tower (6F, Drug product)
- Listed on the KOSDAQ market (February 20)
|
| 2018 |
- Signed contract to move into Magok General Industrial Complex
- Received 'Bio Awards', the 4th Korea Enterprise Awards hosted by Money Today
- Selected by the Ministry of Health and Welfare for BVAC-C phase 2 clinical trial
- Approval of Phase 1 clinical trial for BVAC-B
|
| 2017 |
-
- Approval of phase 2a clinical trial for BVAC-C
- Selected by the Ministry of Trade, Industry and Energy for BVAC-B phase 1 clinical trial and BVAC-P non-clinical trial
|
| 2016 |
-
- Completion of the development of original technology platform, CeliVax.
- Applied for CeliVax trademark
- Selected by the Ministry of Science and ICT for developing new convergence antigens
- Approval of BVAC-C phase 1 clinical trial of BVAC-C
- Selected by the Ministry of SMEs and Startups for BVAC-C phase 1 clinical development
|
| 2015 |
- Selected by the Ministry of SMEs and Startups for BVAC-B development
|
| 2014 |
- Signed an agreement to license out BVAC-C
- Selected by the Ministry of Health and Welfare for BVAC-C non-clinical development
- Secured CeliVax patents
- Received certification of venture company
|
| 2013 |
|
| 2011 |
|
| 2007 |
- Core Patent Application for Immunotherapeutic Vaccine
- Commencement of development of original technology platform, CeliVax
|
| 2006 |
|
